Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Decreased Expression of α-Synuclein, Nogo-A and UCH-L1 in Patients with Schizophrenia: A Preliminary Serum Study.

Demirel ÖF, Cetin İ, Turan Ş, Sağlam T, Yıldız N, Duran A.

Psychiatry Investig. 2017 May;14(3):344-349. doi: 10.4306/pi.2017.14.3.344. Epub 2017 May 16.

2.

Genetic evidence for role of integration of fast and slow neurotransmission in schizophrenia.

Devor A, Andreassen OA, Wang Y, Mäki-Marttunen T, Smeland OB, Fan CC, Schork AJ, Holland D, Thompson WK, Witoelar A, Chen CH, Desikan RS, McEvoy LK, Djurovic S, Greengard P, Svenningsson P, Einevoll GT, Dale AM.

Mol Psychiatry. 2017 Jun;22(6):792-801. doi: 10.1038/mp.2017.33. Epub 2017 Mar 28.

3.

Transcriptional profiling of mitochondria associated genes in prefrontal cortex of subjects with major depressive disorder.

Wang Q, Dwivedi Y.

World J Biol Psychiatry. 2016 Jul 11:1-12. doi: 10.1080/15622975.2016.1197423. [Epub ahead of print]

PMID:
27269743
4.

Candidate gene networks and blood biomarkers of methamphetamine-associated psychosis: an integrative RNA-sequencing report.

Breen MS, Uhlmann A, Nday CM, Glatt SJ, Mitt M, Metsalpu A, Stein DJ, Illing N.

Transl Psychiatry. 2016 May 10;6:e802. doi: 10.1038/tp.2016.67.

5.

Dysregulated 14-3-3 Family in Peripheral Blood Leukocytes of Patients with Schizophrenia.

Qing Y, Sun L, Yang C, Jiang J, Yang X, Hu X, Cui D, Xu Y, He L, Han D, Wan C.

Sci Rep. 2016 Mar 31;6:23791. doi: 10.1038/srep23791.

6.

Proteasome system dysregulation and treatment resistance mechanisms in major depressive disorder.

Minelli A, Magri C, Barbon A, Bonvicini C, Segala M, Congiu C, Bignotti S, Milanesi E, Trabucchi L, Cattane N, Bortolomasi M, Gennarelli M.

Transl Psychiatry. 2015 Dec 1;5:e687. doi: 10.1038/tp.2015.180.

7.

Evidence of Mitochondrial Dysfunction within the Complex Genetic Etiology of Schizophrenia.

Hjelm BE, Rollins B, Mamdani F, Lauterborn JC, Kirov G, Lynch G, Gall CM, Sequeira A, Vawter MP.

Mol Neuropsychiatry. 2015 Dec;1(4):201-19. doi: 10.1159/000441252. Epub 2015 Oct 28. Review. Erratum in: Mol Neuropsychiatry. 2016 May;2(1):60.

8.

Protein Expression of Proteasome Subunits in Elderly Patients with Schizophrenia.

Scott MR, Rubio MD, Haroutunian V, Meador-Woodruff JH.

Neuropsychopharmacology. 2016 Feb;41(3):896-905. doi: 10.1038/npp.2015.219. Epub 2015 Jul 23.

9.

Inhibition of 14-3-3 Proteins Leads to Schizophrenia-Related Behavioral Phenotypes and Synaptic Defects in Mice.

Foote M, Qiao H, Graham K, Wu Y, Zhou Y.

Biol Psychiatry. 2015 Sep 15;78(6):386-95. doi: 10.1016/j.biopsych.2015.02.015. Epub 2015 Feb 19.

10.

A new nosology of psychosis and the pharmacological basis of affective and negative symptom dimensions in schizophrenia.

Vakalopoulos C.

Ment Illn. 2010 May 6;2(1):e7. doi: 10.4081/mi.2010.e7. eCollection 2010 Jan 25. Review.

11.
12.

14-3-3 proteins are required for hippocampal long-term potentiation and associative learning and memory.

Qiao H, Foote M, Graham K, Wu Y, Zhou Y.

J Neurosci. 2014 Apr 2;34(14):4801-8. doi: 10.1523/JNEUROSCI.4393-13.2014.

13.

Postmortem brain: an underutilized substrate for studying severe mental illness.

McCullumsmith RE, Hammond JH, Shan D, Meador-Woodruff JH.

Neuropsychopharmacology. 2014 Jan;39(1):65-87. doi: 10.1038/npp.2013.239. Epub 2013 Oct 4. Review. Erratum in: Neuropsychopharmacology. 2015 Apr;40(5):1307.

14.

Neurobiology of schizophrenia onset.

Woo TU.

Curr Top Behav Neurosci. 2014;16:267-95. doi: 10.1007/7854_2013_243. Review.

15.

Histidine triad nucleotide-binding protein 1 (HINT1) regulates Ca(2+) signaling in mouse fibroblasts and neuronal cells via store-operated Ca(2+) entry pathway.

Linde CI, Feng B, Wang JB, Golovina VA.

Am J Physiol Cell Physiol. 2013 Jun 1;304(11):C1098-104. doi: 10.1152/ajpcell.00073.2013. Epub 2013 Apr 10.

16.

Dysfunction of the ubiquitin proteasome and ubiquitin-like systems in schizophrenia.

Rubio MD, Wood K, Haroutunian V, Meador-Woodruff JH.

Neuropsychopharmacology. 2013 Sep;38(10):1910-20. doi: 10.1038/npp.2013.84. Epub 2013 Apr 9.

17.

Genetics of schizophrenia from a clinicial perspective.

Kukshal P, Thelma BK, Nimgaonkar VL, Deshpande SN.

Int Rev Psychiatry. 2012 Oct;24(5):393-404. doi: 10.3109/09540261.2012.709178. Review.

18.

MAPK14 and CNR1 gene variant interactions: effects on brain volume deficits in schizophrenia patients with marijuana misuse.

Onwuameze OE, Nam KW, Epping EA, Wassink TH, Ziebell S, Andreasen NC, Ho BC.

Psychol Med. 2013 Mar;43(3):619-31. doi: 10.1017/S0033291712001559. Epub 2012 Jul 31.

19.

14-3-3 proteins in neurological disorders.

Foote M, Zhou Y.

Int J Biochem Mol Biol. 2012;3(2):152-64. Epub 2012 May 18.

20.

Transcriptome sequencing revealed significant alteration of cortical promoter usage and splicing in schizophrenia.

Wu JQ, Wang X, Beveridge NJ, Tooney PA, Scott RJ, Carr VJ, Cairns MJ.

PLoS One. 2012;7(4):e36351. doi: 10.1371/journal.pone.0036351. Epub 2012 Apr 27.

Supplemental Content

Support Center